The PARK2 Mutation Associated with Parkinson’s Disease Enhances the Vulnerability of Peripheral Blood Lymphocytes to Paraquat

Table 3

Clinical features of patients in the study sample.

Clinical feature	Patients without mutation	Patients with Parkin mutation
Number	5 [3/2]^a	5 [4/1]^a
Age at disease onset (years)	32.80 ± 2.39	29.80 ± 8.20
Disease duration (years)
Bradykinesia	5 (100)^b	5 (100)^b
Rigidity	5 (100)^b	5 (100)^b
Resting tremor	2 (40)^b	3 (66.7)^b
Postural tremor	1 (20)^b	2 (40)^b
Shuffling gait	2 (40)^b	2 (40)^b
Postural instability	0 (0)^b	1 (20)^b
Hyperreflexia	0 (0)^b	2 (40)^b
Diurnal fluctuations	1 (20)^b	2 (40)^b
Foot dystonia	0 (0)^b	3 (66.7)^b
UPDRS III score at last exam (off state)	19.20 ± 4.32	19.00 ± 5.87

^aValues in square brackets indicate ratios. ^bValues in parentheses indicate percentages.